Prolonged survival in patients with stable disease regardless of histology
Significantly prolonged overall survival in stable disease patients with squamous cell carcinoma by 32%*6
* Stable disease according to RECIST criteria. Overall survival is measured from the time of randomization into the maintenance phase.
Significantly prolonged overall survival in stable disease patients with squamous cell carcinoma by 49%*6
References:
- Stinchcombe TE, Socinski MA. Current treatments for advanced stage non–small cell lung cancer. Proc Am Thorac Soc. 2009;6:233-241.
- Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non–small-cell lung cancer. N Engl J Med. 2006;355:2542-2550.
- Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non–small-cell lung cancer. J Clin Oncol. 2002;20:1335-1343.
- Mok TSK, Ramalingam SS. Maintenance therapy in nonsmall cell lung cancer: a new treatment paradigm. Cancer. 2009;115:5143-5154.
- Sun J-M, Park JO, Won Y-W, et al. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non-small cell lung cancer? Implications for selection of patients for maintenance therapy. J Thorac Oncol. 2010;5:540-545.
- Draft Tarceva® (erlotinib) summary of product characteristics, F. Hoffmann-La Roche Ltd., 2010.
- Shepherd FA, Pereira JR, Ciuleanu T, et al; for the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med. 2005;353:123-132.
- Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2006;24:3831-3837.
- Data on file, OSI Pharmaceuticals, Inc.
- Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11:689-708.
- Data on file, F. Hoffmann-La Roche Ltd.
- Cappuzzo F, Coudert B, Wierzbicki R, et al; on behalf of the SATURN Investigators. Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC). Presented at: European CanCer Organisation (ECCO) 15–34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress; September 20-24, 2009; Berlin, Germany. Abstract 22LBA.
Tarceva.com
This site is only intended for use by healthcare professionals outside of the US. If you are a US resident, please visit www.tarceva.com.
